FROM this month more women
with postmenopausal osteoporosis
will be able to receive
reimbursement for Prolia
(denosumab) following an
expanded listing on the
Pharmaceutical Benefit Scheme.
As such, Prolia (denosumab) is
now listed on the PBS as the sole
anti-resorptive agent for:
established postmenopausal
osteoporosis in a woman with
fracture due to minimal trauma;
and osteoporosis in women aged
70 years of age and older with a
Bone Mineral Density (BMD) Tscore
of -2.5 or less.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 09 Aug 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
